Nanjing Vcare Helps Shanghai Institute of Materia Medica's Anti-cancer Drug LH-1802 Gain Approval for Clinical Research

2021-11-08

On November 5, 2021, LH-1802, an oral anti-cancer drug independently developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, was granted a clinical trial approval letter by the National Medical Products Administration, allowing for clinical trials to begin. The project was undertaken by Nanjing Vcare, which provided efficient "chemistry + pharmacy" industrial chain R&D services from the pre-clinical pharmacology research to the submission of IND registration materials and the full-process key material supply assurance.

LH-1802 project has received funding from national "Major New Drug Creation" Science and Technology Major Project and the Strategic Leading Science and Technology Special Project of the Chinese Academy of Sciences. Systematic preclinical studies have shown that LH-1802 has excellent LSD1 inhibitory activity and selectivity, with good pharmacokinetic characteristics and safety in rats and dogs. It is a safe, effective, and quality-controlled anti-cancer clinical candidate drug with good drug prospects. The clinical trial approval provides a safe and effective potential treatment option for patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

Prev

Nanjing Vcare Assists Nanjing Chiatai Tianqing in Obtaining Lenvatinib Production License